Search research articles
Contact Us
Filters
Showing results (191-200 of 290) with videos related to
Page
of 29
Sort By:
European Urology
|
September 25, 2012
Retrospective comparison of triple-sequence therapies in metastatic renal cell carcinoma
Jonas Busch, Christoph Seidel, Barbara Erber, et al.
World Journal of Urology
|
April 23, 2011
Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors
Steffen Weikert, Carsten Kempkensteffen, Jonas Busch, et al.
Cancer Immunology, Immunotherapy : CII
|
October 31, 2009
Ten-year survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant setting
Matthias May, Sabine Brookman-May, Bernd Hoschke, et al.
Plos One
|
June 30, 2012
Reference miRNAs for miRNAome analysis of urothelial carcinomas
Nadine Ratert, Hellmuth-Alexander Meyer, Monika Jung, et al.
European Urology
|
October 28, 2008
Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis
Manfred Johannsen, Anne Flörcken, Axel Bex, et al.
Clinical Chemistry
|
December 6, 2012
Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer
Carsten Stephan, Klaus Jung, Axel Semjonow, et al.
BJU International
|
October 12, 2013
Higher rates of upgrading and upstaging in older patients undergoing radical prostatectomy and qualifying for active surveillance
Jonas Busch, Ahmed Magheli, Natalia Leva, et al.
Cancer
|
July 13, 2012
Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone
Joel B Nelson, Karim Fizazi, Kurt Miller, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
|
April 30, 2009
Expression of Mcl-1 splicing variants in clear-cell renal cancer and their correlation with histopathological parameters and prognosis
Carsten Kempkensteffen, Stefan Hinz, Manfred Johannsen, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
October 5, 2010
The German S3 guideline prostate cancer: aspects for the radiation oncologist
Frederik Wenz, Thomas Martin, Dirk Böhmer, et al.
Page
of 29
Search research articles
Search
Showing results (191-200 of 290) with videos related to
Sort By:
Page
of 29
European Urology
|
September 25, 2012
Retrospective comparison of triple-sequence therapies in metastatic renal cell carcinoma
Jonas Busch, Christoph Seidel, Barbara Erber, et al.
World Journal of Urology
|
April 23, 2011
Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors
Steffen Weikert, Carsten Kempkensteffen, Jonas Busch, et al.
Cancer Immunology, Immunotherapy : CII
|
October 31, 2009
Ten-year survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant setting
Matthias May, Sabine Brookman-May, Bernd Hoschke, et al.
Plos One
|
June 30, 2012
Reference miRNAs for miRNAome analysis of urothelial carcinomas
Nadine Ratert, Hellmuth-Alexander Meyer, Monika Jung, et al.
European Urology
|
October 28, 2008
Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis
Manfred Johannsen, Anne Flörcken, Axel Bex, et al.
Clinical Chemistry
|
December 6, 2012
Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer
Carsten Stephan, Klaus Jung, Axel Semjonow, et al.
BJU International
|
October 12, 2013
Higher rates of upgrading and upstaging in older patients undergoing radical prostatectomy and qualifying for active surveillance
Jonas Busch, Ahmed Magheli, Natalia Leva, et al.
Cancer
|
July 13, 2012
Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone
Joel B Nelson, Karim Fizazi, Kurt Miller, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
|
April 30, 2009
Expression of Mcl-1 splicing variants in clear-cell renal cancer and their correlation with histopathological parameters and prognosis
Carsten Kempkensteffen, Stefan Hinz, Manfred Johannsen, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
October 5, 2010
The German S3 guideline prostate cancer: aspects for the radiation oncologist
Frederik Wenz, Thomas Martin, Dirk Böhmer, et al.
Page
of 29